Leadboard

Nancy Walsh writing in MedPage Today reported , Most patients with psoriatic arthritis responded well to a firstline biologic, but for many of those who didn’t initially respond, switching to another agent proved beneficial, a researcher reported at the annual meeting of the British Society for Rheumatology. During a retrospective survey that included 548 patients, 74 showed an adequate response to treatment with a tumor necrosis factor TNF inhibitor at 3 months, according to Meghna Jani, MBBS. Meanwhile, among 94 patients who switched to a second TNF inhibitor, 52 responded ‘very well,’ she said.

Leadboard

Leave a Reply